Last updated on July 2018

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies


Brief description of study

The standard or usual treatment for this disease is treatment with drugs and other treatments that may help to make a patient better or may improve their quality of life. This treatment is known as "best supportive care" (BSC). Although patients with best supportive care can feel better for some months, the cancer usually continues to grow.

Detailed Study Description

Durvalumab is a new type of drug for many types of cancer. Laboratory tests show that it works by allowing the immune system to detect cancer and reactivate the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. Durvalumab has been shown to shrink tumours in animals and has been studied in a few people and seems promising but it is not clear if it can offer better results than standard treatment alone. Tremelimumab is a new type of drug for various types of cancers. It works in a similar way to durvalumab and may improve the effect of durvalumab. This may also help slow the growth of the cancer cells or may cause cancer cells to die. Tremelimumab has been shown to shrink tumours in animals and has been studied in a few people and seems promising but it is not clear if it can offer better results than standard treatment alone when used with durvalumab. Combinations of durvalumab and tremelimumab have also been studied and when combined have been shown to increase tumour shrinkage in animals compared to either drug alone and while the combination has been studied in a few people, it is not clear if it can offer better results than standard treatment.

Clinical Study Identifier: NCT02870920

Contact Investigators or Research Sites near you

Start Over

Jose Monzon

Tom Baker Cancer Centre
Calgary, AB Canada

Hagen Kennecke

BCCA - Vancouver Cancer Centre
Vancouver, BC Canada

Mohammed Harb

The Moncton Hospital
Moncton, NB Canada

Chaudhary Ejaz Ahmad

Dr. H. Bliss Murphy Cancer Centre
St. John's, NL Canada

Bruce Colwell

QEII Health Sciences Centre
Halifax, NS Canada

Dawn Ng

Royal Victoria Regional Health Centre
Barrie, ON Canada

John Goffin

Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, ON Canada

Anna Tomiak

Cancer Centre of Southeastern Ontario at Kingston
Kingston, ON Canada

John Lenehan

London Regional Cancer Program
London, ON Canada

Derek Jonker

Ottawa Hospital Research Institute
Ottawa, ON Canada

Ioannis Voutsadakis

Algoma District Cancer Program
Sault Ste. Marie, ON Canada

Scott Berry

Odette Cancer Centre
Toronto, ON Canada

Eric (Xueyu) Chen

University Health Network
Toronto, ON Canada

Sindu Mary Kanjeekal

Windsor Regional Cancer Centre
Windsor, ON Canada

Benoit Samson

Hopital Charles LeMoyne
Greenfield Park, QC Canada

Nathalie Aucoin

Hopital de la Cite-de-la-Sante
Laval, QC Canada

Felix Couture

L'Hotel-Dieu de Levis
Levis, QC Canada

Francine Aubin

CHUM - Hopital Notre-Dame
Montreal, QC Canada

Petr Kavan

The Jewish General Hospital
Montreal, QC Canada

Setareh Samimi

Centre Integre Universitaire De Sante Et De Services
Montreal, QC Canada

Felix Couture

CHUQ-Pavillon Hotel-Dieu de Quebec
Quebec City, QC Canada

Frederic Lemay

Centre hospitalier universitaire de Sherbrooke
Sherbrooke, QC Canada

Anouk Tremblay

Centre hospitalier regional de Trois-Rivieres
Trois-Rivieres, QC Canada

Muhammad Salim

Allan Blair Cancer Centre
Regina, SK Canada

Shahid Ahmed

Saskatoon Cancer Centre
Saskatoon, SK Canada